Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Webinars
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • AI and healthcare
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
      • Top Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • AI and healthcare
    • Industry Perspective
  • Home
  • News
  • Industry
  • Pharma News
  • Indian Pharma Market...

Indian Pharma Market Grows 10.7% in August Despite Volume Growth Losing Steam

Written By : Susmita Roy Published On 2026-09-08T20:45:46+05:30  |  Updated On 8 Sept 2026 8:45 PM IST
Indian Pharma Market Kicks Off 2026 With 10% Growth in January: PharmaTrac
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

New Delhi: The Indian Pharmaceutical Market (IPM) grew 10.7% in value to reach Rs 23,272 crore in August 2026, even as volume growth moderated slightly from the levels recorded during the preceding three months, according to the latest PharmaTrac Industry Report.

The market, however, recorded no growth in overall unit volumes during August, indicating that its value expansion was supported by price growth and new product introductions rather than higher aggregate volumes. On a moving annual total (MAT) basis, the IPM was valued at Rs 2,58,977 crore, reflecting value growth of 10.4% and unit growth of 1%.

AIOCD President J S Shinde and General Secretary Rajiv Singhal informed that from the AIOCD perspective, this trend highlights the importance of ensuring that the growth of the pharmaceutical industry is accompanied by sustainable trade margins, healthy inventory movement, reasonable credit terms and protection of the traditional distribution network. The report also shows pressure on volumes in important segments such as Anti-Infectives and Respiratory, which deserves attention from all stakeholders.

The rapid growth of GLP-1 therapies, particularly Tirzepatide and Semaglutide, is another important development and indicates a changing therapy landscape.

AIOCD believes that future pharmaceutical growth must be balanced with the interests of patients, manufacturers, distributors and the 12.40 lakh+ licensed chemists and pharmacists who form the backbone of medicine availability across the country.

PharmaTrac noted that all three market growth levers—volume, price and new products—remained positive during August. Quarterly growth for the period ended August 2026 stood at 11.9%, comprising price growth of 6%, new-product growth of 3.6% and volume growth of 2.3%.

Therapy-wise, cardiac medicines remained the largest segment, recording August sales of Rs 3,229 crore and value growth of 15.1%. Unit volumes increased by 3.2%. On a MAT basis, the cardiac market reached Rs 36,506 crore, accounting for approximately 14.1% of the IPM.

Also Read:Recalls by Dr Reddy's, Torrent Put Spotlight on Quality Standards in India's Semaglutide Market

The gastrointestinal segment generated monthly sales of Rs 2,762 crore and grew 10.8% in value, supported by unit growth of 1.7%. Anti-infectives recorded sales of Rs 2,674 crore but reported comparatively subdued value growth of 2.7%, along with a 5.5% decline in unit volumes.

The anti-diabetic market grew 15% in August to Rs 2,197 crore, with unit growth of 2.1%. Vitamins, minerals and nutrients registered one of the strongest performances among the major therapy segments, growing 16.2% to Rs 2,185 crore, accompanied by unit growth of 4.2%.

Respiratory therapies generated Rs 1,616 crore during the month but grew only 2.2% in value, while unit volumes declined by 5.6%. The report identified respiratory medicines and anti-infectives as two of the larger therapy segments facing negative volume growth during August.

Pain and analgesic medicines grew 11.3% to Rs 1,675 crore, while neuro and central nervous system therapies also expanded 11.3%, reaching Rs 1,542 crore. Dermatology products posted value growth of 12.5% to Rs 1,489 crore, supported by unit growth of 2.9%.

Gynaecological therapies grew 14.2% to Rs 759 crore, while blood-related medicines increased 12.3% to Rs 709 crore. Antineoplastics reported value growth of 14.2% and sales of Rs 569 crore, whereas urology products grew 14.1% to Rs 421 crore.

Vaccines generated sales of Rs 230 crore during August and recorded value growth of 11.9%, accompanied by unit growth of 12.1%. In contrast, hormones grew only 1.3% in value and reported an 11% decline in unit volumes. Anti-malarials contracted by 11.5% in value and 7.8% in units.

A major focus of the PharmaTrac report was the rapid expansion of the GLP-1 agonist market. The combined solid and injectable GLP-1 agonist segment was valued at Rs 2,333 crore on a MAT basis. Tirzepatide accounted for Rs 1,456 crore, representing approximately 62% of the segment, while semaglutide contributed Rs 782 crore, or 34%. Dulaglutide and liraglutide held considerably smaller shares.

Within injectable GLP-1 agonists, the market was valued at Rs 2,010 crore. Tirzepatide dominated with a share of about 72%, followed by semaglutide at approximately 23%. PharmaTrac observed that injectable products appeared to be gaining preference over solid formulations following the launch of injectable tirzepatide and semaglutide in 2025.

The report indicated that the GLP-1 agonist market had begun stabilising following its initial surge after the introduction of generic products. Demand for solid semaglutide appeared to decline during August, potentially reflecting a shift towards injections due to their lower dosing frequency. Tirzepatide unit volumes recorded a slight decline during the month, although its value trend continued to rise, possibly due to movement towards higher-dose and multidose presentations.

At the corporate level, Sun Pharma retained its leadership with August sales of Rs 1,954 crore, an 8.4% market share and value growth of 13.9%. Abbott ranked second for the month with sales of Rs 1,350 crore and growth of 8.1%, while Mankind Pharma occupied the third position with sales of Rs 1,305 crore and growth of 9%.

Cipla recorded August sales of Rs 1,298 crore and value growth of 12.1%, followed by Torrent Pharma at Rs 1,197 crore, with growth of 15.1%. Alkem posted sales of Rs 996 crore and grew 13.9%, while Intas recorded Rs 921 crore and value growth of 11.1%.

Lupin grew 14.4% to Rs 834 crore, while Zydus reported one of the strongest performances among the top companies, growing 19.1% to Rs 738 crore. Dr Reddy’s Laboratories generated sales of Rs 723 crore and registered value growth of 11.6%.

Among the other leading companies, Glenmark and Eris Lifesciences recorded monthly value growth of 16.7% each. USV grew 12.6%, GSK 9.7%, IPCA 9.7%, Aristo Pharma 9.3%, Micro Labs 8.2% and Macleods 6.9%. Emcure recorded comparatively modest growth of 2.9%.

Among companies ranked between 21 and 40 on a MAT basis, Corona registered August value growth of 22%, while La Renon grew 19.3%, Hetero 19.2%, Ajanta Pharma 14.8% and FDC 12.8%. Eli Lilly grew 19.4% in value during the month, although its unit volumes declined by 58.2%, reflecting the impact of its high-value GLP-1 portfolio.

At the brand level, Eli Lilly’s Mounjaro retained the number-one position in both the MAT and monthly rankings. The brand generated MAT sales of Rs 1,256 crore, representing growth of 502.1%, and August sales of Rs 112 crore. During the month, its value grew 34.1%, although unit volumes declined 43.8%.

GSK’s Augmentin ranked second with MAT sales of Rs 957 crore, followed by USV’s Glycomet GP at Rs 950 crore. During August, Augmentin generated Rs 94 crore and grew 5.5%, while Glycomet GP recorded sales of Rs 85 crore and value growth of 14.1%.

Cipla’s Foracort, Alkem’s Pan, IPCA’s Zerodol SP, Abbott’s Mixtard, Alkem’s Clavam, Himalaya’s Liv.52 and Alkem’s Pan D completed the top ten MAT brand rankings.

Zerodol SP delivered particularly strong monthly growth of 45.2% in value and 35.5% in units. Torrent Pharma’s Cilacar grew 36.6% in value and 24.9% in units, while Abbott’s Ryzodeg recorded value and unit growth of 23.5% and 23.7%, respectively. Glenmark’s Telma grew 15.6% in value and 12.1% in units.

Other brands showing robust value and unit growth during August included Sun Pharma’s Levipil and Rosuvas, FDC’s Electral, AstraZeneca’s Brilinta, Cipla’s Dytor, GSK’s Calpol and Torrent Pharma’s Chymoral Forte. Rosuvas recorded value growth of 40.3%, while Chymoral Forte grew 28%, Brilinta 24.3% and Electral 21.8%.

Also Read:India's GLP-1 Market Nears Rs 2,000 Crore as Semaglutide Boom Slows, Tirzepatide Regains Momentum

To view the report, click the link below:

https://medicaldialogues.in/pdf_upload/2026/09/08/ipm-performance-pharmatrac-mat-aug-2026-474724.pdf
https://medicaldialogues.in/pdf_upload/2026/09/08/pharmatrac-industry-maileraug-2026-474725.pdf
pharmatracIndian pharmaceutical marketpharmatrac reportMounjarotirzepatidesemaglutideGLP1sun pharmaAbbottciplaTorrent Pharma

Medical Survey

Susmita Roy
Susmita Roy

    Mpharm (Pharmacology)

    Susmita Roy, B pharm, M pharm Pharmacology, graduated from Gurunanak Institute of Pharmaceutical Science and Technology with a bachelor's degree in Pharmacy. She is currently working as an assistant professor at Haldia Institute of Pharmacy in West Bengal. She has been part of Medical Dialogues since March 2021.

    Print Article
    Show Full Article
    Next Story
    Recommended For You
    NO DATA FOUND

    Editorial

    Dapagliflozin Metformin in T2D: Five Evidence Insights Relevant for Clinicians

    Dapagliflozin Metformin in T2D: Five Evidence Insights Relevant for Clinicians

    Jural Exploitation of Healthcare Professionals and Institutions in the PM-RAHAT Scheme - Dr Rajeev Joshi

    Jural Exploitation of Healthcare Professionals and Institutions in the PM-RAHAT Scheme - Dr Rajeev...

    Metformin - Eight Points on a Metabolic Anchor in T2D: World Diabetes Day Special

    Metformin - Eight Points on a Metabolic Anchor in T2D: World Diabetes Day Special

    Clinical Insights for Allergic Rhinitis Management with Fexofenadine and Pseudoephedrine Combination - Dr. Makarand Damle

    Clinical Insights for Allergic Rhinitis Management with Fexofenadine and Pseudoephedrine Combination...

    Effect of Saroglitazar in MASLD: Latest Indian 2026 Study

    Effect of Saroglitazar in MASLD: Latest Indian 2026 Study

    View All

    Journal Club Today

    Scientists Discover Surprising Role of Vitamin B12 in Correcting Genetic Disorder-Related Defects

    Scientists Discover Surprising Role of Vitamin B12 in Correcting Genetic Disorder-Related Defects

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok